CME/CE from MPR


MPR delivers practical, up-to-date drug information to healthcare professionals. Using the expertise gained from 25 years of providing point-of-care drug tools, MPR has now created a drug review course exclusively for myCME.com. See below for a list of each quarter's courses. Click here to visit MPR's website.




Latest Courses

Clinical Review

New Drug Review from MPR (April 2014)

1.00 Credits
Clinical Review

New Drug Review from MPR (October 2013)

1.00 Credits
HM 



Archived CME/CE Courses

HM 


MPR Drug News


Government Plan to Fight Antibiotic-Resistant Bacteria Announced

The President's Council of Advisors on Science and Technology (PCAST) has released the report Combating Antibiotic Resistance to the President in conjunction with the National Strategy on Combating Antibiotic Resistant Bacteria and the Presidential Executive Order on the importance of addressing this concerning issue.

AACE/ACE Position Statement: Obesity is a Chronic Disease

The American Association of Clinical Endocrinologist (AACE) and the American College of Endocrinology (ACE) announced the publication of its position statement that describes its framework for a new diagnosis of obesity as a chronic disease.

Lymphoseek Gains Orphan Drug Designation for Head, Neck Cancer Detection

Navidea announced that the Food and Drug Administration (FDA) has granted Lymphoseek (technetium Tc 99m tilmanocept) injection an Orphan Drug Designation for use in sentinel lymph node detection in patients with head and neck cancer.

Xultophy Shows Improved Glycemic Control, Weight Loss in T2DM

Novo Nordisk announced new data from the Phase 3a DUAL clinical trial comparing Xultophy (insulin degludec and liraglutide [IDegLira]) to insulin degludec (Tresiba) and liraglutide (Victoza) alone in insulin-naive and insulin-treated patients.

Effects of Antihypertensives Last for T2DM Patients, Even After Stopping Tx

Reductions in heart events and death last for many years after stopping therapy in patients with type 2 diabetes that take antihypertensives, Australian researchers have found.